Gene expression changes in rat asbestos-induced malignant mesothelioma (MM) cells were investigated by dierential mRNA display. A mRNA transcript identi®ed by this approach was abundant in normal rat mesothelial cells but not expressed in rat MM cell lines. Northern blot analysis con®rmed that this transcript is uniformly silenced in rat MM cell lines and primary tumors. Nucleotide sequence analysis revealed that this transcript is encoded by the rat glypican 3 gene (GPC3), whose human homolog is mutated in the SimpsonGolabi-Behmel overgrowth syndrome. Allelic loss at the GPC3 locus was infrequent (6.9%) in MM cell lines, and no mutations were found. GPC3 transcript levels were markedly decreased in 16 of 18 primary tumors and 17 of 22 human MM cell lines. Most of the cell lines were shown to have aberrant methylation of the GPC3 promoter region. In two of four human MM cell lines tested, GPC3 expression was restored after 2-deoxy 5-azacytidine (DAC)-mediated demethylation of its promoter region. Ectopic expression of GPC3 inhibited in vitro colony formation of human MM cells. Collectively, these data suggest that down-regulation of GPC3 is a common occurrence in MM and that GPC3, an X-linked recessive overgrowth gene, may encode a negative regulator of mesothelial cell growth. Oncogene (2000) 19, 410 ± 416.
Introduction
MM is an asbestos-related neoplasm arising primarily from the surface serosal cells of the pleural, peritoneal, and pericardial cavities (Craighead, 1987; Wagner et al., 1960; Mossman and Gee, 1989) . To investigate molecular genetic changes associated with mesothelial cell tumorigenesis, experimental animal models have been created by exposing rodents to asbestos ®bers Wagner et al., 1973; Hill et al., 1990) . Because of the similarities in the pathogenesis and histogenesis of human and rat asbestos-induced MMs, cell lines derived from the induced tumors have been used as models for biological studies of this disease (Davis, 1974; Funaki et al., 1991; Libbus and Craighead, 1988) . The accumulation of numerous clonal chromosomal deletions in most human MMs suggests a multistep process of tumorigenesis, characterized by the loss and/or inactivation of multiple tumor suppressor genes. Positional cloning and candidate gene strategies have led to the identi®cation of two tumor suppressor genes that are frequently altered in MM, i.e., CDKN2A/INK4a, encoding p16 and p14 ARF , and NF2 (Cheng et al., 1994; Sekido et al., 1995; Bianchi et al., 1995) .
To identify additional genes that may contribute to the initiation or progression of MM, we have investigated gene expression changes in rat asbestosinduced MM cells by dierential mRNA display (Liang and Pardee, 1992; Zou et al., 1994) . Using this approach, we have identi®ed a transcript that is transcriptionally silenced in rat MM cells. Sequence analysis of the cDNA encoding this transcript revealed that the down-regulated gene is GPC3 (also known as OCI-5), which encodes a developmentally regulated cell membrane proteoglycan, glypican 3 (Filmus et al., 1988 (Filmus et al., , 1995 . Human GPC3 is mutated in the SimpsonGolabi-Behmel syndrome, an X-linked disorder characterized by prenatal and postnatal overgrowth, numerous morphological abnormalities, and increased risk of embryonal tumors of mesodermal origin (Pilia et al., 1996) . We also report marked down-regulation of GPC3 in many human MM tumor specimens and cell lines and demonstrate that ectopic expression of GPC3 inhibits growth of MM cells in culture.
cells (data not shown). One of these transcripts is discussed in this report. To con®rm the dierential mRNA display ®nding, the cDNA fragment of interest was recovered from the gel, radiolabeled, and hybridized to a Northern blot of mRNA isolated from normal and malignant cells. This analysis con®rmed that the transcript corresponding to this cDNA fragment is abundant in both normal mesothelial cell lines but is silenced in all peritoneal and pleural MM cell lines tested (Figure 1) . Moreover, Northern blot analysis of two rat asbestos-induced primary MMs showed no detectable expression of GPC3 (data not shown).
The dierentially expressed cDNA fragment was subcloned and sequenced. Similarity searches, based on the nucleotide sequence of the cDNA, was performed using BLAST and GCG programs. These analyses revealed that the cDNA fragment is identical to sequences of the rat GPC3 gene (Filmus et al., 1988) .
Down-regulation of GPC3 in human MM specimens and cell lines
To examine the expression status of GPC3 in human MM cells, Northern blot analysis was performed with total RNA from control mesothelial cells and MM cell lines. Expression of GPC3 was not detectable in any of the cell lines (data not shown); however, RT-PCR analysis revealed decreased expression of GPC3 in all MM cell lines compared to controls (Figure 2a, upper panel) . (T08, T10 ). mRNA was fractionated in a 1.5% agarose gel and transferred onto a nylon membrane. The down-regulated GPC3 cDNA isolated by dierential display was used as a probe in the hybridization. The blots were rehybridized with a GAPDH cDNA probe to normalize the RNA loading A similar pattern of downregulation of GPC3 was obtained by amplifying a smaller (*360-bp) GPC3 cDNA fragment, comparable in size to the *400-bp GAPDH control. Thus, these data indicate that down-regulation of GPC3 is not only a common occurrence in human MM cell lines but also in many primary MM tumors.
Allelic loss and mutational analysis
To determine the frequency of allelic loss in the vicinity of the human GPC3 gene, we examined four microsatellite markers in the region Xq25-q27.1 anking the GPC3 locus at Xq26.1, as well as a ®fth marker located at Xq22. Overall, allelic loss was observed in only 6.9% of cases (two of six females; 0 of 23 males). Both of the aected females showed losses at all informative loci, suggesting loss of a large segment of the X chromosome. To determine whether GPC3 is mutated in MM, SSCP analysis was performed on genomic DNA from 14 human MM cell lines. No band shifts were observed in PCR products ampli®ed with primers corresponding to portions of six exons of GPC3, when compared to normal control DNA. SSCP analysis was also carried out using puri®ed RT-PCR products from four MM cell lines that showed decreased levels of expression of GPC3 compared to controls. No mutations were detected in any of the samples tested.
Methylation of the GPC3 promoter in human MM cells
Since the human GPC3 promoter contains a 5' CpG island, we examined methylation of speci®c CpG sites in human MM cells. EcoRI-digested genomic DNA yielded an *8-kb fragment containing GPC3 promoter sequences (Lin et al., 1999) . Co-digestion with EagI or KspI, two methylation-sensitive restriction enzymes, produces a 4.2-kb fragment, if the CpG island is unmethylated. Co-digestion with BssHII, another methylation sensitive enzyme, produces several different restriction fragments (Figure 3a) , depending on the methylation status of individual CpG sites. The restriction fragments were detected by Southern blot analysis using a probe containing an 880-bp portion of the promoter region of GPC3. As shown in Figure 3b , co-digestion with EcoRI and EagI detected aberrant methylation in eight cell lines; four of these cell lines exhibited only the *8-kb fragment characteristic of the hypermethylated allele, and four others displayed both *8-kb and 4.2-kb fragments, suggesting that some cells have a methylated GPC3 allele and others retain an unmethylated allele. Co-digestion with EcoRI and KspI showed aberrant methylation in two additional cell lines (data not shown). Methylation analysis with BssHII demonstrated aberrant methylation patterns in 17 of the 22 MM cell lines (Figure 3c ). The GPC3 methylation status did not closely parallel the degree of down-regulation of this gene. For example, among the 17 cell lines with aberrant methylation, ®ve did not have markedly decreased transcript levels, although the expression of GPC3 was reduced compared to normal mesothelial cells. Furthermore, among the ®ve cell lines without hypermethylation of the GPC3 promoter, two (Meso-10, -41) showed very low transcript levels.
Treatment of human MM cell lines with DAC demethylating reagent
To determine if methylation is responsible for the decreased expression of GPC3, four human MM cell were treated with the DAC. RT-PCR analysis of these samples demonstrated re-expression of GPC3 in two (Meso-17 and -19) cell lines (Figure 3d ), suggesting that promoter methylation is responsible for down-regulated expression of GPC3 in these two cell lines.
Growth inhibition of human MM cells by GPC3
To assess the eect of loss of GPC3 expression on growth of human MM cells, a GPC3 expression construct was transfected into two human MM cell lines (HMESO and Meso-17) lacking detectable endogenous expression of this gene. Northern and Western blot analyses of pooled clones of transfected cells con®rmed the ectopic expression of GPC3 (Figure 4a,b) . Ectopic expression of GPC3 produced a marked reduction in colony-forming eciency (Table 1) .
Discussion
We have used dierential mRNA display to identify a gene that is silenced in rat asbestos-induced MM and down-regulated in many human MMs. This differentially expressed gene, GPC3, encodes a developmentally regulated, heparan sulfate proteoglycan that is bound to the cell surface through a glycosylphosphatidylinositol anchor (Filmus et al., 1988 (Filmus et al., , 1995 . Based on their localization on the cell surface, such glypicans are thought to regulate interactions between growth factors and their receptors (David, 1993) . Indeed, there is a growing body of evidence supporting this notion. For example, cotransfection experiments with K562 cells demonstrated that glypican 1 can stimulate basic ®broblast growth factor (FGF) and FGF receptor-1 interactions and signaling, and that cell-surface association may enhance this eect (Steinfeld et al., 1996) . The eect of GPC1 is not always stimulatory, however, since it has been shown that this glypican can inhibit the ability of keratinocyte growth factor to activate its receptor in rat myoblasts (Bonneh-Barkay et al., 1997) .
At the present time, it is not known which growth factors are regulated by GPC3. Simpson-GolabiBehmel syndrome is very similar to BeckwithWiedemann syndrome, another overgrowth disorder. Since biallelic expression of insulin-like growth factor 2 (IGF-2) has been associated with Beckwith-Wiedemann syndrome, it has been proposed that GPC3 is a negative regulator of IGF-2 (Pilia et al., 1996) . Although we have not been able to detect a direct interaction between GPC3 and IGF-2 (Song et al., 1997) , it is possible that GPC3 negatively regulates IGF-2 activity by interacting with a component of its signaling system. In addition, it is also possible that GPC3 regulates the activity of other growth factors such as members of the FGF (Song et al., 1997) , transforming growth factor-b, and Wnt families, since it has been shown that GPC3, like other heparan sulfate proteoglycans, can bind to`heparin binding' growth factors.
The role of GPC3 in the development of cancer is not known. We previously showed that membranebound GPC3 induces programmed cell death in cell lines derived from a rat MM and a human breast cancer (Gonzalez et al., 1998) . Induction of apoptosis is cell line-speci®c, because such a response was not elicited in human HT-29 colorectal tumor cells or NIH3T3 ®broblasts. The data summarized in this report reveal that GPC3 is uniformly silenced in rat MMs and down-regulated in many human MM tumor specimens and tumor-derived cell lines. Similarly, silencing of GPC3 has recently been reported in four of 13 cell lines from human ovarian carcinomas (Lin et al., 1999) which, like MMs, are derived from coelomic epithelium. In each of the four ovarian cancer cell lines, down-regulation of GPC3 was associated with aberrant promoter methylation, and expression of GPC3 was restored by treatment with DAC. In MM, down-regulation of GPC3 was also associated with aberrant methylation of the GPC3 promoter region. However, we were not able to demonstrate reactivation of GPC3 expression by DAC in every human MM cell line. In addition, DAC treatment did not reactivate expression of GPC3 in any of the ten rat MM cell lines (data not shown). Thus, in MM, promoter methylation does not appear to be the sole mechanism involved in down-regulating GPC3. Other factors, such as histone deacetylase inhibition (Cameron et al., 1999) , may also be required for robust re-expression of GPC3 in MM. In non-cancerous ®broblast-like cells, Huber et al., (1999) showed that DAC treatment does not reactivate GPC3, possibly due to the inability of this demethylating agent to reverse tissue-speci®c forms of regulation that do not depend on hypermethylation. These investigators concluded that nonexpressing cells may not produce a transcription factor required for GPC3 expression or, alternatively, could produce a repressor that silences this gene. Furthermore, transfection with active H-ras and v-src has been shown to irreversibly abolish GPC3 expression in IEC-18 cells (Filmus et al., 1988) , suggesting that the down-regulation may also be due to the oncogenic activation of certain repressive transcription factors that regulate expression of GPC3.
Our data indicate that stable ectopic expression of GPC3 can inhibit in vitro colony formation of human MM cells lacking endogenous expression of this gene. Similarly, re-expression of GPC3 suppressed the growth of ovarian cancer cells in vitro, and it has been proposed that the GPC3 product functions as a tumor suppressor in the ovary (Lin et al., 1999) . Growth inhibition is considered a characteristic of tumor suppressors (Baker et al., 1990) , and promoter hypermethylation has been reported for some tumor suppressor genes (Herman et al., 1994) . However, unlike other tumor suppressor genes, mutations or homozygous deletions of GPC3 have not been identi®ed in cancer cells to date. Hence, in MM down-regulation of GPC3 may represent a secondary (downstream) event, rather than a primary oncogenic target. Nevertheless, the association between GPC3 mutations and overgrowth of various organs in Simpson-Golabi-Behmel syndrome suggests a potentially critical role of GPC3 in maintaining the homeostatic balance between cell growth and cell death, which is disrupted in tumorigenesis. Moreover, considering the relationship of GPC3 to cell shape and morphogenesis (Filmus et al., 1988 (Filmus et al., , 1995 , loss of expression of this glypican may contribute to tumor invasiveness characteristic of many MMs. Future investigations of GPC3 signaling and the identi®cation of speci®c proteins that activate or repress transcription of GPC3 will facilitate a better understanding of the role of GPC3 in tumorigenesis.
Materials and methods

Tumor specimens and cell lines
All rodent normal mesothelial cells and MM cell lines were derived from female Fisher 344 rat tissues. Normal rat mesothelial cell lines RPM-I and RPM-II were isolated from the pleural mesothelium (Janssen et al., 1995) . MM cell lines Mes-I-22, Mes-I-22.03, Mes-II-11, Mes-II-14, Mes-II-22, Mes-II-39, Mes-II-52, and Mes-II-57 were derived from peritoneal tumors induced by asbestos Libbus and Craighead, 1988) . These normal and tumor cell lines were cultured in DMEM and F-12 (Gibco) (1 : 1) supplemented with transferrin and selenium (Collaborative Research), hydrocortisone and insulin (Sigma), and 10% fetal calf serum (FCS). MM cell lines T08 and T10 were established from asbestosinduced pleural tumors and were grown in DMEM supplemented with 10% FCS. The diploid human mesothelial cell line LP-9 (Coriell Institute for Medical Research), used as a control, was cultured in Medium 199 in Earle's BSS/MCDB (1 : 1) supplemented with epidermal growth factor, hydrocortisone, and 20% FCS. Additional control human mesothelial cells, obtained from a pericardial eusion of a patient with congestive heart failure but no malignancy, were grown in RPMI 1640 medium supplemented with 10% FCS. Primary human MM specimens were obtained from newly diagnosed patients and stored at 7708C prior to analysis. MM cell lines were established from surgically explanted primary tumors as described previously (Taguchi et al., 1993) and grown in RPMI 1640 with 10% FCS.
Dierential mRNA display
Total RNA (200 ng) was reverse-transcribed using primers 5'-TTTTTTTTTTTTM(G, A, or C)A-3', 5'-TTTTTTTT-TTTTMC-3', or 5'-TTTTTTTTTTTTMG-3'. Reverse transcription-polymerase chain reaction (RT-PCR) was carried out at 608C for 5 min, 378C for 60 min, and 958C for 5 min. The cDNA generated was subsequently ampli®ed by PCR using each of the following ten arbitrary primers: 5'-AGCCAGCGAA-3', 5'-GACCGCTTGT-3', 5'-AGGT- in the presence of [a-32 P]-dCTP. Thermocycling was performed as follows: 948C for 30 s, 408C for 30 s, and 728C for 30 s for 40 cycles. The PCR products were separated in a 6% denaturing polyacrylamide gel. The gel was dried and exposed to X-ray ®lm at 7808C.
Northern blot and RT-PCR expression analysis
Polyadenylated RNA (2 mg) or total RNA (15 mg) from normal rat mesothelial cells and rat MM cells was resolved by electrophoresis in a 1% agarose/2.2 M formaldehyde gel and then blotted onto a Duralon-UV nylon membrane (Stratagene). PCR products recovered from the dierential display gels were radiolabeled with a-32 P-dCTP using a random labeling kit (Boehringer Mannheim) and hybridized overnight to RNA blots. After washing at high stringency, hybridization signals were visualized by autoradiography.
Total RNA isolated from two control human mesothelial cell lines (500 ng per cell line) and 22 MM cell lines (5 mg per cell line) was reverse-transcribed using the primer 5'-AGTAACTTGCAGTGACTTGGA-3' to generate a GPC3 cDNA fragment and primer 5'-ATGATCTTGAGGCT-GTTGTC-3' to generate a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA fragment, the latter used as an internal control. RT-PCR was performed at 658C for 5 min, 428C for 30 min, and 958C for 5 min. The cDNAs were ampli®ed by PCR with the primer 5'-CTCTA-CATCTTGGGTTCTGA-3' for GPC3 and the primer 5'-AGTCAACGGATTTGGTCGTA-3' for GAPDH. The cycling parameters were as follows: 948C for 30 s, 568C for 30 s, and 728C for 1 min for 25 cycles. The RT-PCR products were electrophoresed in a 1% agarose gel containing ethidium bromide and transferred to a Gene Screen Plus nylon membrane (Dupont NEN). The Southern blot was hybridized to a radiolabeled probe generated using primers 5'-GTGGATGATATGGTCAATGA-3' and 5'-GGAAAC-TGCCAAATACTTTC-3', which recognize GPC3. Total RNA was isolated from 18 human MM tumor specimens and two normal lung tissue samples, and 5 mg of total RNA per sample was reverse transcribed using an oligo-dT primer. Primers 5'-GTTACTGCATATGTGGTCATGC-3' and 5'-ACATGTGCTGGGCACCAG-3' were used to amplify an *990-bp fragment of human GPC3 cDNA. As an internal control, a GAPDH fragment was ampli®ed as described above.
DNA cloning and sequencing
A PCR fragment abundant in normal rat mesothelial cells but silenced in rat MM cells was cloned into plasmid pGEM-T (Promega). The insert was sequenced using an ABI PRISM 377 DNA Sequencer (Perkin Elmer).
Allelic loss and mutational analysis
Five microsatellite markers (DXS8089, DXS1206, DXS1047, DXS1232, and HPRT)¯anking the GPC3 locus at Xq26.1 were examined. Primer pairs used for PCR ampli®cation of dinucleotide repeat markers were obtained from Research Genetics. In each case, 20 ng of genomic DNA was ampli®ed in a 5-ml reaction volume with 0.1 mCi of [a-32 P]-dCTP using a Hybaid programmable thermal cycler. Ampli®cation conditions consisted of an initial denaturation for 5 min at 948C, followed by 35 cycles of 1 min at 948C, 1 min at 578C, and 1 min at 728C, and then by a 10-min extension at 728C. PCR products were diluted 1 : 1 with a 95% formamide gel-loading buer; 3 ml of each PCR product was separated on a 6% polyacrylamide sequencing gel. Gels were dried at 808C under vacuum and subjected to autoradiography at 7708C for 2 h. For single strand conformation polymorphism (SSCP) analysis of genomic DNA, oligonucleotide primers were identical to those reported for genomic PCR ampli®cation of individual exons (Pilia et al., 1996) . For cDNA analyses, RT-PCR with two sets of overlapping primer pairs was used to amplify the complete GPC3 cDNA from four human MMs. SSCP analysis of these cDNAs were performed with ten overlapping oligonucleotide primer pairs to scan the entire cDNA. Nucleotide sequence analysis was performed with an ABI-PRISM automated sequencing apparatus (Perkin Elmer).
Methylation analysis
For Southern analysis of the methylation status of the GPC3 promoter, we used 10 mg of genomic DNA isolated from each of 22 human MM cell lines and peripheral blood from two normal donors. DNA was digested with EcoRI alone or in combination with EagI, BssHII, or KspI. The digested DNA was fractionated in a 0.8% agarose gel, transferred to nylon membrane (Dupont NEN), and hybridized with a radiolabeled 880-bp, PCR-generated DNA fragment from the promoter region of GPC3. Human MM cell lines were examined for restoration of GPC3 expression by treating with the demethylating reagent DAC (Sigma). Cells were seeded at 50% con¯uence, cultured for 24 h, and treated with 1 mM DAC for 5 days. Drug-containing medium was replenished daily. Total RNA was isolated and analysed by RT-PCR as described above.
Ectopic expression of GPC3 in human MM cells
Hemagglutinin (HA) epitope-tagged human GPC3 cDNA was cloned into pEF-BOS vector (Gonzalez et al., 1998) . Vector alone was used as a control. Two human MM cell lines, HMESO and Meso-17, were transfected using Lipofectamine (Gibco BRL) according to the manufacturer's protocols. Stably-transfected cells were selected for 14 days with neomycin (400 mg/ml), ®xed in 10% formalin, stained with 0.2% crystal violet, and then the number of colonies formed by cells transfected with the expression construct or vector alone were counted. Each transfection was repeated several times, and two dierent preparations of each plasmid were used. Ectopic expression of GPC3 in HMESO and Meso-17 was demonstrated by Northern and Western blot analyses. Total cell lysates were prepared as previously described (Gonzalez et al., 1998) and quantitated using the Bradford colorimetric assay. Equal amounts of denatured protein were separated electrophoretically in a 7.5% SDS ± PAGE gel, transferred to PVDF membrane (Dupont NEN), and the resulting Western blot was blocked with 5% non-fat milk in phosphate buered saline. The blot was incubated with HA11 mouse HAmonoclonal antibody (Babco) at a dilution of 1 : 1000 with 1% non-fat milk in PBS buer. Human GPC3 was visualized with the ECL detection system (Amersham).
